Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:9/10/2008

SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at two investor conferences in September:

-- Merriman Curhan Ford's 5th Annual Investor Summit to be held at the Mark Hopkins InterContinental Hotel in San Francisco on Monday, September 15, 2008 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time); and

-- UBS's 2008 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on Tuesday, September 23, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation date.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact

Robert H. Uhl Senior Director, Investor Relations

(858) 704-8264

ruhl@halozyme.com

Media Contacts

Karen Sparks / Joleen Schultz

Mentus

(858) 455-5500, x275/x215

karen@mentus.com

jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
4. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
5. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
6. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
9. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
10. Halozyme Therapeutics Amends Stockholder Rights Plan
11. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics ... Mark its Chlamydia trachomatis (CT) test to be launched on ... IVD Directive (98/79/EC), the CT test is now cleared for ... --> The launch of the io® CT test ...
(Date:2/6/2016)... Virginia (PRWEB) , ... February 06, 2016 , ... ... E-mail: amitchell(at)cee(dot)org , The Center for Excellence in Education Sponsors Teacher Training ... VA – February 4, 2016 – The Center for Excellence in Education (CEE) ...
(Date:2/5/2016)... CHAPEL HILL, N.C. , Feb. 5, 2016 /PRNewswire/ ... a key role for a host of launch activities ... The importance of this launch activity is especially high ... are specialists. Best Practices and the Role ... study will help companies focused on oncology therapies find ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):